Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus MYTELASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus MYTELASE.
EDROPHONIUM CHLORIDE PRESERVATIVE FREE vs MYTELASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment.
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%).
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor